Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kura Oncology, Inc. - Common Stock (NQ:KURA)

8.670 -0.180 (-2.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kura Oncology, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Micron, Charles River Laboratories And Some Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining more than 80 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Kura Oncology Stock Joins Rank Of Stocks With RS Ratings Over 90 ↗
On Monday, Kura Oncology stock had its Relative Strength (RS) Rating upgraded to 91, up from 85 a day earlier. 
Via Investor's Business Daily
News headline image
7 Cheap Biotech Stocks to Buy Now ↗
These cheap biotech stocks to buy offer investors a way to get ready for the inevitable comeback in the biopharmaceutical sector. 
Via InvestorPlace
News headline image
Earnings Preview: Kura Oncology ↗
Kura Oncology (NASDAQ:KURA) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement. Analysts estimate that Kura... 
Via Benzinga
News headline image
Read Why Did Credit Suisse Raise Price Target On Kura Oncology ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Kura Oncology Stock Scores Rising Relative Strength ↗
On Thursday, Kura Oncology stock had its Relative Strength (RS) Rating stock upgraded to 93 from 81 a day earlier. 
Via Investor's Business Daily
News headline image
PreMarket Prep: Looking For Biotech Bargains With This Wedbush Analyst ↗
Biotechnology is one sector that peaked ahead of the S&P 500 index. While the S&P 500 index did not peak until January, the SPDR Biotech (NYSE: XBI) peaked in February 2021 and is now 60% lower than... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal 
Via Benzinga
News headline image
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More ↗
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion. 
Via Benzinga
News headline image
Kura Oncology, Inc. (NASDAQ:KURA) Investor Notice: Investigation over Potential Wrongdoing ↗
San Diego, CA -- (SBWIRE) -- 03/04/2022 -- Certain directors of Kura Oncology, Inc are under investigation over potential breaches of fiduciary duties. 
Via SBWire
News headline image
Kura Oncology: Q4 Earnings Insights ↗
Kura Oncology (NASDAQ:KURA) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 15, 2022 ↗
Upgrades For Blue Bird Corp (NASDAQ:BLBD), Roth Capital upgraded the previous rating of Neutral to Buy. Blue Bird earned $0.07 in the first quarter, compared to $0.00 in the year-... 
Via Benzinga
Groundbreaking Clinical Trials Accelerating New Treatment Options for Pancreatic Cancer
Palm Beach, FL – February 2, 2022 – FinancialNewsMedia.com News Commentary – In the battle against pancreatic cancer, new and innovative clinical trials have become extremely critical. These trials... 
Via FinancialNewsMedia
News headline image
The Daily Biotech Pulse: Kura Lifts Clinical Hold On Blood Cancer Trial, Intuitive Surgical Earnings, Sorrento's Omicron Antibody Treatment Effective ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kura Announces Lifting Of Clinical Hold On Phase 1 Blood Cancer Study Kura... 
Via Benzinga
News headline image
FDA Lifts Partial Hold On Kura Oncology's Early-Stage Leukemia Trial ↗
The FDA has lifted the partial clinical hold on Kura Oncology Inc (NASDAQ: KURA) KOMET-001 Phase 1b study of KO-539 in patients with relapsed or refractory... 
Via Benzinga
News headline image
NASDAQ:KURA Investor Notice: Investigation over Possible Securities Laws Violations by Kura Oncology, Inc. ↗
San Diego, CA -- (SBWIRE) -- 12/09/2021 -- Kura Oncology, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
News headline image
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
News headline image
68 Biggest Movers From Wednesday ↗
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) shares gained 689.4% to settle at $78.94 on Wednesday after the company priced its IPO at $10 per share. Longeveron Inc. (... 
Via Benzinga
Topics Initial Public Offering
News headline image
40 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Biofrontera Inc. (NASDAQ: BFRI) shares jumped 109.5% to $5.51 after Roth Capital initiated coverage on the stock with a Buy rating and a $20 price target. Longeveron Inc... 
Via Benzinga
News headline image
Why Kura Oncology Stock Is Sliding Today ↗
A partial clinical hold for the company's experimental leukemia treatment is making investors nervous. 
Via The Motley Fool
News headline image
See Why FDA Hit Red Light On Kura's Early-Stage Leukemia Trial ↗
The FDA has slapped a partial clinical hold on the early-stage program for one of Kura Oncology Inc’s (NASDAQ: KURA) cancer drugs following a patient... 
Via Benzinga
News headline image
FDA Slams Kura Oncology With A Clinical Hold — And Investors Slam Its Stock ↗
Kura can continue to treat patients, but it can't enroll new patients in its study. 
Via Investor's Business Daily
Topics Death
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Ocuphire Pharma (NASDAQ:OCUP) stock rose 78.73% to $6.22 during Wednesday's pre-market session. The market value of their outstanding shares is at $107.6... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Kura's Blood Cancer Drug Study Gets Partial Clinical Hold, Takeda FDA Nod, Puma Breast Cancer Treatment Gets Patent Extension ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Puma Biotech Announces Receipt Of Patent Extension For Breast Cancer Drug By... 
Via Benzinga
Topics Intellectual Property
News headline image
Kura Oncology, inc (KURA) Q3 2021 Earnings Call Transcript ↗
KURA earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
News headline image
Jon Najarian Sees Unusual Options Activity In Lucid Motors, Kura Oncology And More ↗
Jon Najarian spoke on CNBC's "Options Action" about unusually high options activity in Lucid Group Inc (NASDAQ: LCID) on Tuesday. He said options traders are buying... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.